Article detail · 2007
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis
- Year
- 2007
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue WORLD JOURNAL OF GASTROENTEROLOGY
- Catalog match (ISSN) World Journal of Gastroenterology
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
OpenAlex · English
AIM: To investigate whether serum levels of two soluble forms of extracellular cytokeratin 18 (M30-antigen and M65-antigen) may differentiate nonalcoholic steatohepatitis (NASH) from simple steatosis in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: A total of 83 patients with suspected NAFLD and 49 healthy volunteers were investigated. Patients with suspected NAFLD were classified according to their liver histology into four groups: definitive NASH (n=45), borderline NASH (n=24), simple fatty liver (n=9), and normal tissue (n=5). Serum levels of caspase-3 generated cytokeratin-18 fragments (M30-antigen) and total cytokeratin-18 (M65-antigen) were determined by ELISA. RESULTS: Levels of M30-antigen and M65-antigen were significantly higher in patients with definitive NASH compared to the other groups. An abnormal value (> 121.60 IU/L) of M30-antigen yielded a 60.0% sensitivity and a 97.4% specificity for the diagnosis of NASH. Sensitivity and specificity of an abnormal M65-antigen level (> 243.82 IU/L) for the diagnosis of NASH were 68.9% and 81.6%, respectively. Among patients with NAFLD, M30-antigen and M65-antigen levels distinguished between advanced fibrosis and early-stage fibrosis with a sensitivity of 64.7% and 70.6%, and a specificity of 77.3% and 71.2%, respectively. CONCLUSION: Serum levels of M30-antigen and M65-antigen may be of clinical usefulness to identify patients with NASH. Further studies are mandatory to better assess the role of these apoptonecrotic biomarkers in NAFLD pathophysiology.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
169 citations
OpenAlex cited_by_count (cache / database)
22 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- Apoptosis: why and how does it occur in biology? 2011
- Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease 2012
- Serum concentrations of human insulin like growth factor 1 and levels of insulin like growth factor binding protein 5 in patients with nonalcoholic fatty liver disease 2012
- Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis 2009
- A glance at the methods for detection of apoptosis qualitatively and quantitatively 2011
- Is Alanine Aminotransferase Level a Surrogate Biomarker of Hepatic Apoptosis in Nonalcoholic Fatty Liver Disease? 2010
- Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels 2009
- A “Biomarker Biopsy” for the Diagnosis of NASH: Promises from CK-18 Fragments 2008
- Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B 2010
- Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease 2009